Literature DB >> 2417744

Pharmacology of the bipyridines: amrinone and milrinone.

A A Alousi, D C Johnson.   

Abstract

The cardiovascular bipyridines amrinone and milrinone are positive inotropic agents with vasodilator properties. When their effects on the heart and circulation were studied in both isolated cardiac tissues and anesthetized animals, milrinone was found to be 30 times more potent than amrinone. The inotropic response of isolated atria and papillary muscles to the bipyridines was characterized by increases in isometric tension and in the rates of tension development and relaxation. In the anesthetized dog, amrinone (1.0 mg/kg iv) and milrinone (0.03 mg/kg iv) caused significant increases in left ventricular dP/dtmax, cardiac output, and heart rate, significant decreases in pulmonary arterial pressure, and no change in systemic blood pressure. Studies to elucidate the mechanism(s) of action of the bipyridines indicated that Ca++ and cyclic AMP (cAMP) play important roles. The inotropic response to milrinone was modified by changes in the rate of stimulation and the concentration of extracellular Ca++ and by depolarization with high K+ or pretreatment with a calcium-channel blocker. Reduction of the extracellular Na+ concentration of 75% of normal potentiated the inotropic response of papillary muscles to low concentrations of milrinone, suggesting possible activation of the Na+-Ca++ exchange mechanism. These results suggest that milrinone may stimulate the influx of Ca++ into the cardiac cell. The bipyridines are phosphodiesterase inhibitors that increase cardiac cAMP levels. However, a time-course analysis of the changes in cAMP levels during the inotropic response to the bipyridines indicated that the increase in isometric tension development preceded the increase in cAMP. Our data suggest that more than one mechanism may be involved in the initiation and maintenance of the inotropic response to the bipyridines.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2417744

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

Review 1.  Use of inotropes and vasopressor agents in critically ill patients.

Authors:  Mansoor N Bangash; Ming-Li Kong; Rupert M Pearse
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Incidence of milrinone blood levels outside the therapeutic range and their relevance in children after cardiac surgery for congenital heart disease.

Authors:  Gonzalo Garcia Guerra; Ari R Joffe; Ambikaipakan Senthilselvan; Demetrios J Kutsogiannis; Christopher S Parshuram
Journal:  Intensive Care Med       Date:  2013-02-22       Impact factor: 17.440

Review 3.  Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.

Authors:  H von der Leyen
Journal:  Klin Wochenschr       Date:  1989-06-15

Review 4.  The interface between monitoring and physiology at the bedside.

Authors:  Eliezer L Bose; Marilyn Hravnak; Michael R Pinsky
Journal:  Crit Care Clin       Date:  2015-01       Impact factor: 3.598

Review 5.  Management of sepsis and septic shock in infants and children.

Authors:  N von Rosenstiel; I von Rosenstiel; D Adam
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  Milrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  R A Young; A Ward
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

7.  Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart.

Authors:  D Brunkhorst; H v der Leyen; W Meyer; R Nigbur; C Schmidt-Schumacher; H Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

Review 8.  Studies on the mechanism of action of the bipyridine milrinone on the heart.

Authors:  A E Farah; C J Frangakis
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 9.  Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.

Authors:  T A Fischer; R Erbel; N Treese
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

Review 10.  Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.

Authors:  Yuan James Rao; Lei Xi
Journal:  Acta Pharmacol Sin       Date:  2008-12-08       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.